10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
| Autor: | Masip, J. Remon, Besse, B., Aix, S. Ponce, Perez, A. Callejo, Al-Rabi, K., Caro, R. Bernabe, Greillier, L., Tarruella, M. Majem, Aransay, N. Reguart, Monnet, I., Cousin, S., Lopez, P. Garrido, Robinet, G., Campelo, R. García, Flandin, A-C. Madroszyk, Mazieres, J., Curcio, H., Pretzenbacher, Y., Dingemans, A-M.C., Dziadziuszko, R. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology April 2023 18(4) Supplement:S35-S35 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|